Susquehanna International Group
NRIX icon

Susquehanna International Group’s Nurix Therapeutics NRIX Stock Holding History

Susquehanna International Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Buy
81,455
+30,902
+61% +$512K ﹤0.01% 7299
2025
Q4 		$959K Sell
50,553
-33,806
-40% -$486K ﹤0.01% 7291
2025
Q3 		$779K Sell
84,359
-6,561
-7% -$68.1K ﹤0.01% 7927
2025
Q2 		$1.04M Sell
90,920
-14,751
-14% -$159K ﹤0.01% 7341
2025
Q1 		$1.26M Buy
105,671
+55,985
+113% +$936K ﹤0.01% 6685
2024
Q4 		$936K Buy
49,686
+29,214
+143% +$670K ﹤0.01% 7132
2024
Q3 		$460K Sell
20,472
-36,719
-64% -$832K ﹤0.01% 8658
2024
Q2 		$1.19M Buy
57,191
+6,662
+13% +$104K ﹤0.01% 6165
2024
Q1 		$743K Sell
50,529
-22,011
-30% -$237K ﹤0.01% 7575
2023
Q4 		$749K Buy
72,540
+14,818
+26% +$102K ﹤0.01% 7704
2023
Q3 		$454K Sell
57,722
-33,159
-36% -$303K ﹤0.01% 8463
2023
Q2 		$908K Buy
90,881
+23,322
+35% +$238K ﹤0.01% 6908
2023
Q1 		$600K Buy
67,559
+42,793
+173% +$446K ﹤0.01% 8116
2022
Q4 		$272K Sell
24,766
-24,387
-50% -$294K ﹤0.01% 9335
2022
Q3 		$640K Buy
49,153
+33,378
+212% +$528K ﹤0.01% 7804
2022
Q2 		$200K Sell
15,775
-20,388
-56% -$231K ﹤0.01% 10631
2022
Q1 		$507K Sell
36,163
-5,751
-14% -$102K ﹤0.01% 8934
2021
Q4 		$1.21M Buy
41,914
+10,103
+32% +$306K ﹤0.01% 6767
2021
Q3 		$953K Buy
31,811
+4,596
+17% +$142K ﹤0.01% 7682
2021
Q2 		$722K Sell
27,215
-29,703
-52% -$872K ﹤0.01% 8667
2021
Q1 		$1.77M Buy
+56,918
New +$2.15M ﹤0.01% 6220

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Susquehanna International Group's NRIX Position: Q1 2026 in Review

Susquehanna International Group increased its Nurix Therapeutics (NRIX) stake by 61% in Q1 2026, buying an estimated $512K and bringing the position to 81,455 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #7299.

Susquehanna International Group first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.77M in Q1 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Susquehanna International Group held 81,455 shares of Nurix Therapeutics worth $1.26M as of Q1 2026.
  • Susquehanna International Group bought 30,902 Nurix Therapeutics shares in Q1 2026, an estimated $512K.
  • Nurix Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7299 holding.
  • Susquehanna International Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Susquehanna International Group's Nurix Therapeutics position peaked at $1.77M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.